Download PDF
CC BY-NC-ND 4.0 · J Lab Physicians 2020; 12(03): 230-232
DOI: 10.1055/s-0040-1720944
Others

In Vitro activity of a Novel Benzoquinolizine Antibiotic, Levonadifloxacin (WCK 771) against Blood Stream Gram-Positive Isolates from a Tertiary Care Hospital

Dhruv Mamtora
1   Department of Microbiology, S.L. Raheja Hospital, Mumbai, Maharashtra, India
,
Sanjith Saseedharan
2   Department of Critical Care Medicine, S.L. Raheja Hospital, Mumbai, Maharashtra, India
,
Ritika Rampal
3   Department of Medical Affairs, Wockhardt Ltd., Mumbai, Maharashtra, India
,
Prashant Joshi
4   Drug Discovery Research, Wockhardt Research Center, Aurangabad, Maharashtra, India
,
Pallavi Bhalekar
1   Department of Microbiology, S.L. Raheja Hospital, Mumbai, Maharashtra, India
,
Jaishid Ahdal
3   Department of Medical Affairs, Wockhardt Ltd., Mumbai, Maharashtra, India
,
Rishi Jain
3   Department of Medical Affairs, Wockhardt Ltd., Mumbai, Maharashtra, India
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

Background Blood stream infections (BSIs) due to Gram-positive pathogens such as methicillin-resistant Staphylococcus aureus (MRSA) are associated with high mortality ranging from 10 to 60%. The current anti-MRSA agents have limitations with regards to safety and tolerability profile which limits their prolonged usage. Levonadifloxacin and its oral prodrug alalevonadifloxacin, a novel benzoquinolizine antibiotic, have recently been approved for acute bacterial skin and skin structure infections including diabetic foot infections and concurrent bacteremia in India.

Methods The present study assessed the potency of levonadifloxacin, a novel benzoquinolizine antibiotic, against Gram-positive blood stream clinical isolates (n = 31) collected from January to June 2019 at a tertiary care hospital in Mumbai, India. The susceptibility of isolates to antibacterial agents was defined following the Clinical and Laboratory Standard Institute interpretive criteria (M100 E29).

Results High prevalence of MRSA (62.5%), quinolone-resistant Staphylococcus aureus (QRSA) (87.5%), and methicillin-resistant coagulase-negative staphylococci (MR-CoNS) (82.35%) were observed among bacteremic isolates. Levonadifloxacin demonstrated potent activity against MRSA, QRSA, and MR-CoNS strains with significantly lower minimum inhibitory concentration MIC50/90 values of 0.5/1 mg/L as compared with levofloxacin (8/32 mg/L) and moxifloxacin (2/8 mg/L).

Conclusion Potent bactericidal activity coupled with low MICs support usage of levonadifloxacin for the management of BSIs caused by multidrug resistant Gram-positive bacteria.

Keywords

blood stream infections - methicillin-resistant S. aureus - levonadifloxacin - quinolone-resistant S. aureus


Publication History

Article published online:
23 November 2020

© 2020. The Indian Association of Laboratory Physicians. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • References

  • 1 Bassetti M, Righi E, Carnelutti A. Bloodstream infections in the intensive care unit. Virulence 2016; 7 (03) 267-279
    CrossrefPubMedGoogle Scholar
  • 2 Indian Network for Surveillance of Antimicrobial Resistance (INSAR) group, India. Methicillin resistant Staphylococcus aureus (MRSA) in India: prevalence & susceptibility pattern. Indian J Med Res 2013; 137 (02) 363-369
    PubMedGoogle Scholar
  • 3 Prowle JR, Echeverri JE, Ligabo EV. et al. Acquired bloodstream infection in the intensive care unit: incidence and attributable mortality. Crit Care 2011; 15 (02) R100
    CrossrefPubMedGoogle Scholar
  • 4 Bassetti M, Trecarichi EM, Mesini A. et al. Risk factors and mortality of healthcare-associated and community-acquired Staphylococcus aureus bacteraemia. Clin Microbiol Infect 2012; 18 (09) 862-869
    CrossrefPubMedGoogle Scholar
  • 5 Pastagia M, Kleinman LC, Lacerda de la Cruz EG, Jenkins SG. Predicting risk for death from MRSA bacteremia. Emerg Infect Dis 2012; 18 (07) 1072-1080
    CrossrefPubMedGoogle Scholar
  • 6 Nguyen HM, Graber CJ. Limitations of antibiotic options for invasive infections caused by methicillin-resistant Staphylococcus aureus: is combination therapy the answer?. J Antimicrob Chemother 2010; 65 (01) 24-36
    CrossrefPubMedGoogle Scholar
  • 7 Narita M, Tsuji BT, Yu VL. Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome. Pharmacotherapy 2007; 27 (08) 1189-1197
    CrossrefPubMedGoogle Scholar
  • 8 Potashman MH, Formella DN, Hamed K, Mohr JF. Comment on: efficacy and safety of daptomycin for the treatment of infectious disease: a meta-analysis based on randomized controlled trials. J Antimicrob Chemother 2015; 70 (04) 1274-1275
    CrossrefPubMedGoogle Scholar
  • 9 Cui L, Tominaga E, Neoh HM, Hiramatsu K. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2006; 50 (03) 1079-1082
    CrossrefPubMedGoogle Scholar
  • 10 Bhagwat SS, Mundkur LA, Gupte SV, Patel MV, Khorakiwala HF. The anti-methicillin-resistant Staphylococcus aureus quinolone WCK 771 has potent activity against sequentially selected mutants, has a narrow mutant selection window against quinolone-resistant Staphylococcus aureus, and preferentially targets DNA gyrase. Antimicrob Agents Chemother 2006; 50 (11) 3568-3579
    CrossrefPubMedGoogle Scholar
  • 11 Bhagwat SS, Nandanwar M, Kansagara A. et al. Levonadifloxacin, a novel broad-spectrum anti-MRSA benzoquinolizine quinolone agent: review of current evidence. Drug Des Devel Ther 2019; 13: 4351-4365
    CrossrefPubMedGoogle Scholar
  • 12 Clinical and Laboratory Standard Institute (CLSI). 11th ed. 2018
    Google Scholar
  • 13 Clinical and Laboratory Standard Institute (CLSI). 29th ed. 2019
    Google Scholar
  • 14 Flamm RK, Farrell DJ, Sader HS, et al. In Vitro Activity of WCK 771, a Benzoquinolizine Fluoroquinolone (Levonadifloxacin) when Tested Against Contemporary Gram-Positive and -Negative Bacteria from a Global Surveillance Program. Poster: Sunday 456, MICROBE, June 16–20, 2016. Boston, MA, USA
  • 15 Appalaraju B, Baveja S, Baliga S. et al. In vitro activity of a novel antibacterial agent, levonadifloxacin, against clinical isolates collected in a prospective, multicentre surveillance study in India during 2016-18. J Antimicrob Chemother 2020; 75 (03) 600-608
    CrossrefPubMedGoogle Scholar